Pediatric Drugs

, Volume 17, Issue 2, pp 125–140 | Cite as

Use of Quetiapine in Children and Adolescents

  • Gabriele Masi
  • Annarita Milone
  • Stefania Veltri
  • Raffaella Iuliano
  • Chiara Pfanner
  • Simone Pisano
Review Article
First Online:

Abstract

The atypical antipsychotic quetiapine has been used in different psychotic and non-psychotic disorders in children and adolescents in randomized clinical trials, open-label studies and chart reviews. Most of these studies suggest that quetiapine may be a promising agent with a potential for use in young patients. The aim of this paper is to critically review available literature on quetiapine in the treatment of children and adolescents with a variety of psychiatric disorders, including psychotic disorders, bipolar disorders (manic and depressive episodes), conduct disorder, autism spectrum disorder, Tourette’s syndrome and personality disorders. Furthermore, we report on possible neurochemical pathways involved during treatment with quetiapine, and discuss some issues that are clinically relevant in daily practice, such as titration strategies, safety and tolerability, and monitoring possible side effects. Controlled studies support the short-term efficacy for treating psychosis, mania, and aggression within certain diagnostic categories. However, although quetiapine seems well tolerated in various pediatric populations during acute and intermediate treatments, and hyper-prolactinemia and extra-pyramidal side effects are consistently low among studies, weight gain and alterations in lipid profile need to be closely monitored. Furthermore, the distal benefit/risk ratio during long-term treatment remains to be determined.

Keywords

Autism Spectrum Disorder Risperidone Olanzapine Borderline Personality Disorder Quetiapine 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

Notes

Conflict of interest

Dr. Masi was on the advisory boards for Eli Lilly, Shire and Angelini, has received research grants from Eli Lilly and Shire, and has been a speaker for Eli Lilly, Shire, Lundbeck and Otsuka. Dr. Pfanner has received research grants from Eli Lilly and Shire and has been a speaker for Eli Lilly and Shire. Drs. Milone, Veltri, Iuliano and Pisano do not have any conflicts of interest to declare.

References

  1. 1.
    Sikich L, Fraziet JA, McClellan J, Findling RL, Vitiello B, Ambler D, Puglia M, Maloney AE, Michael E, DeJong S, Slifka K, Noyes N, Hlastala S, Pierson L, McNamara NK, DelPorto-Bedoya D, Anderson R, Hamer RM, Lieberman JA. Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizoaffective disorders: findings from the Treatment of Early-Onset Schizophrenia Spectrum Disorders (TEOSS) study. Am J Psychiatry. 2008;165:1420–31.CrossRefPubMedGoogle Scholar
  2. 2.
    Baeza I, de la Serna E, Calvo-Escalona R, Morer A, Merchán-Naranjo J, Tapia C, Martínez-Cantarero MC, Andrés P, Alda JA, Sánchez B, Arango C, Castro-Fornieles J. Antipsychotic use in children and adolescents: a 1-year follow-up study. J Clin Psychopharmacol. 2014;34:613–9.CrossRefPubMedGoogle Scholar
  3. 3.
    Findling RL. Use of quetiapine in children and adolescents. J Clin Psychiatry. 2002;63(suppl 13):27–31.PubMedGoogle Scholar
  4. 4.
    Winter HR, Earley WR, Hamer-Maansson JE, Davis PC, Smith MA. Steady-state pharmacokinetic, safety, and tolerability profiles of quetiapine, norquetiapine, and other quetiapine metabolites in pediatric and adult patients with psychotic disorders. J Child Adolesc Psychopharmacol. 2008;18:81–98.CrossRefPubMedGoogle Scholar
  5. 5.
    McConville BJ, Arvanitis LA, Thyrun PT, Yeh C, Wilkinson LA, Chaney RO, Foster KD, Sorter MT, Friedman LM, Brown KL, Heubi JE. Pharmacokinetics, tolerability, and clinical effectiveness of quetiapine fumarate: an open-label trial in adolescents with psychotic disorders. J Clin Psychiatry. 2000;61:252–60.CrossRefPubMedGoogle Scholar
  6. 6.
    Findling RL, Reed MD, O’Riordan MA, Demeter CA, Stansbrey RJ, McNamara NK. Effectiveness, safety, and pharmacokinetics of quetiapine in aggressive children with conduct disorder. J Am Acad Child Adolesc Psychiatry. 2006;45:792–800.CrossRefPubMedGoogle Scholar
  7. 7.
    Johnson TN, Zhou D, Bui KH. Development of physiologically-based pharmacokinetic model to evaluate the relative systemic exposure to quetiapine after administration of IR and XR formulations to adults, children and adolescents. Biopharm Drug Dispos. 2014;35:341–52.CrossRefPubMedGoogle Scholar
  8. 8.
    Shaw JA, Lewis JE, Pascal S, Sharma RK, Rodriguez RA, Guillen R, Pupo-Guillen M. A study of quetiapine: efficacy and tolerability in psychotic adolescents. J Child Adolesc Psychopharmacol. 2001;11:415–24.CrossRefPubMedGoogle Scholar
  9. 9.
    Schimmelmann BG, Mehler-Wex C, Lambert M, Schulze-zur-Wiesch C, Koch E, Flechtner HH, Gierow B, Maier J, Meyer E, Schulte-Markwort M. A prospective 12-week study of quetiapine in adolescents with schizophrenia spectrum disorders. J Child Adolesc Psychopharmacol. 2007;17:768–78.CrossRefPubMedGoogle Scholar
  10. 10.
    Findling RL, McKenna K, Earley WR, Stankowski J, Pathak S. Efficacy and safety of quetiapine in adolescents with schizophrenia investigated in a 6-week, double-blind, placebo-controlled trial. J Child Adolesc Psychopharmacol. 2012;22:327–42.CrossRefPubMedGoogle Scholar
  11. 11.
    Jensen JB, Kumra S, Leitten W, Oberstar J, Anjum A, White T, Wozniak J, Lee SS, Schulz SC. A comparative pilot study of second-generation antipsychotics in children and adolescents with schizophrenia-spectrum disorders. J Child Adolesc Psychopharmacol. 2008;18:317–26.CrossRefPubMedGoogle Scholar
  12. 12.
    Arango C, Robles O, Parellada M, Fraguas D, Ruiz-Sancho A, Medina O, Zabala A, Bombín I, Moreno D. Olanzapine compared to quetiapine in adolescents with a first psychotic episode. Eur Child Adolesc Psychiatr. 2009;18:418–28.CrossRefGoogle Scholar
  13. 13.
    Castro-Fornieles J, Parellada M, Soutullo CA, Baeza I, Gonzalez-Pinto A, Graell M, Paya B, Moreno D, de la Serna E, Arango C. Antipsychotic treatment in child and adolescent first-episode psychosis: a longitudinal naturalistic approach. J Child Adolesc Psychopharmacol. 2008;18:327–36.CrossRefPubMedGoogle Scholar
  14. 14.
    Swadi HS, Craig BJ, Pirwani NZ, Black VC, Buchan JC, Bobier CM. A trial of quetiapine compared with risperidone in the treatment of first onset psychosis among 15- to 18-year-old adolescents. Int Clin Psychopharmacol. 2010;25:1–6.CrossRefPubMedGoogle Scholar
  15. 15.
    Robles O, Zabala A, Bombín I, Parellada M, Moreno D, Ruiz-Sancho A, Arango C. Cognitive efficacy of quetiapine and olanzapine in early-onset first-episode psychosis. Schizophr Bull. 2011;37:406–15.CrossRefGoogle Scholar
  16. 16.
    Pathak S, Findling RL, Earley WR, Acevedo LD, Stankowski J, DelBello MP. Efficacy and safety of quetiapine in children and adolescents with mania associated with bipolar I disorder: a 3-week, double-blind, placebo-controlled trial. J Clin Psychiatry. 2013;74:100–9.CrossRefGoogle Scholar
  17. 17.
    DelBello MP, Schwiers ML, Rosenberg HL, Strakowski SM. A double-blind, randomized, placebo-controlled study of quetiapine as adjunctive treatment for adolescent mania. J Am Acad Child Adolesc Psychiatry. 2002;41:1216–23.CrossRefPubMedGoogle Scholar
  18. 18.
    DelBello MP, Kowatch RA, Adler CM, Stanford KE, Welge JA, Barzman DH, Nelson E, Strakowski SM. A double-blind randomized pilot study comparing quetiapine and divalproex for adolescent mania. J Am Acad Child Adolesc Psychiatry. 2006;45:305–13.CrossRefPubMedGoogle Scholar
  19. 19.
    DelBello MP, Adler CM, Whitsel RM, Stanford KE, Strakowski SM. A 12-week single-blind trial of quetiapine for the treatment of mood symptoms in adolescents at high risk for developing bipolar I disorder. J Clin Psychiatry. 2007;68:789–95.CrossRefPubMedGoogle Scholar
  20. 20.
    Joshi G, Petty C, Wozniak J, Faraone SV, Doyle R, Georgiopoulos A, Hammerness P, Walls S, Glaeser B, Brethel K, Yorks D, Biederman J. A prospective open-label trial of quetiapine monotherapy in preschool and school age children with bipolar spectrum disorder. J Affect Disord. 2012;136:1143–53.CrossRefPubMedGoogle Scholar
  21. 21.
    Scheffer RE, Tripathi A, Kirkpatrick FG, Schultz T. Rapid quetiapine loading in youths with bipolar disorder. J Child Adolesc Psychopharmacol. 2010;20:441–5.CrossRefPubMedGoogle Scholar
  22. 22.
    DelBello MP, Chang K, Welge JA, Adler CM, Rana M, Howe M, Bryan H, Vogel D, Sampang S, Delgado SV, Sorter M, Strakowski SM. A double-blind, placebo-controlled pilot study of quetiapine for depressed adolescents with bipolar disorder. Bipolar Disord. 2009;11:483–93.CrossRefPubMedGoogle Scholar
  23. 23.
    Findling RL, Pathak S, Earley WR, Liu S, DelBello MP. Efficacy and safety of extended-release quetiapine fumarate in youth with bipolar depression: an 8-week, double-blind, placebo-controlled trial. J Child Adolesc Psychopharmacol. 2014;24:325–35.CrossRefPubMedGoogle Scholar
  24. 24.
    Barzman DH, DelBello MP, Adler CM, Stanford KE, Strakowski SM. The efficacy and tolerability of quetiapine versus divalproex for the treatment of impulsivity and reactive aggression in adolescents with co-occurring bipolar disorder and disruptive behavior disorder(s). J Child Adolesc Psychopharmacol. 2006;16:665–70.CrossRefPubMedGoogle Scholar
  25. 25.
    Masi G, Pisano S, Milone A, Pfanner C, Manfredi A. Quetiapine monotherapy in adolescents with bipolar disorder comorbid with conduct disorder. J Child Adolesc Psychopharmacol. 2013;23:568–71.CrossRefPubMedCentralPubMedGoogle Scholar
  26. 26.
    Connor DF, McLaughlin TJ, Jeffers-Terry M. Randomized controlled pilot study of quetiapine in the treatment of adolescent conduct disorder. J Child Adolesc Psychopharmacol. 2008;18:140–56.CrossRefPubMedGoogle Scholar
  27. 27.
    Findling RL, Reed MD, O’Riordan MA, Demeter CA, Stansbrey RJ, McNamara NK. A 26-week open-label study of quetiapine in children with conduct disorder. J Child Adolesc Psychopharmacol. 2007;17:1–9.CrossRefPubMedGoogle Scholar
  28. 28.
    Kronenberger WG, Giauque AL, Lafata DE, Bohnstedt BN, Maxey LE, Dunn DW. Quetiapine addition in methylphenidate treatment-resistant adolescents with comorbid attention-deficit/hyperactivity disorder, conduct/oppositional-defiant disorder, and aggression: a prospective, open-label study. J Child Adolesc Psychopharmacol. 2007;17:334–47.CrossRefPubMedGoogle Scholar
  29. 29.
    Findling RL, McNamara NK, Gracious BL, O’Riordan MA, Reed MD, Demeter C, Blumer JL. Quetiapine in nine youths with autistic disorder. J Child Adolesc Psychopharmacol. 2004;14:287–94.CrossRefPubMedGoogle Scholar
  30. 30.
    Hardan AY, Jou RJ, Handen BL. Retrospective study of quetiapine in children and adolescents with pervasive developmental disorders. J Autism Dev Disord. 2005;35:387–91.CrossRefPubMedGoogle Scholar
  31. 31.
    Golubchik P, Sever J, Weizman A. Low-dose quetiapine for adolescents with autistic spectrum disorder and aggressive behavior: open-label trial. Clin Neuropharmacol. 2011;34:216–9.CrossRefPubMedGoogle Scholar
  32. 32.
    Podobnik J, Foller Podobnik I, Grgic N, Marcinko D, Pivac N. The effect of add-on treatment with quetiapine on measures of depression, aggression, irritability and suicidal tendencies in children and adolescents. Psychopharmacology. 2012;20:639–41.CrossRefGoogle Scholar
  33. 33.
    Mukaddes NM, Abali O. Quetiapine treatment in children and adolescents with Tourette’s disorder. J Child Adolesc Psychopharmacol. 2003;13:295–9.CrossRefPubMedGoogle Scholar
  34. 34.
    Copur M, Arpaci B, Demir T, Nacir H. Clinical effectiveness of quetiapine in children and adolescents with Tourette’s syndrome: a retrospective case-note survey. Clin Drug Invest. 2007;27:123–30.CrossRefGoogle Scholar
  35. 35.
    Copur M, Hergüner S, Arpaci B. Tolerability of quetiapine in children and adolescents with Tourette’s syndrome. Int J Clin Pharmacol Ther. 2011;49:177–8.PubMedGoogle Scholar
  36. 36.
    Gilbert DL, Batterson JR, Sethuraman G, Sallee FR. Tic reduction with risperidone versus pimozide in a randomized, double blind cross-over trial. J Am Acad Child Adolesc Psychiatry. 2004;43:206–14.CrossRefPubMedGoogle Scholar
  37. 37.
    Yoo HK, Joung YS, Lee JS, Song DH, Lee YS, Kim JW, Kim BN, Cho SC. A multicenter, randomized, double-blind, placebo controlled of aripiprazole in children and adolescents with Tourette’s disorder. J Clin Psychiatry. 2013;74:e772–80.CrossRefPubMedGoogle Scholar
  38. 38.
    Chang K, DelBello M, Chu WJ, Garrett A, Kelley R, Mills N, Howe M, Bryan H, Adler C, Eliassen J, Spielman D, Strakowski SM. Neurometabolite effects of response to quetiapine and placebo in adolescents with bipolar depression. J Child Adolesc Psychopharmacol. 2012;22:261–8.CrossRefPubMedCentralPubMedGoogle Scholar
  39. 39.
    Adler CM, DelBello MP, Weber WA, Jarvis KB, Welge J, Chu WJ, Rummelhoff E, Kim MJ, Lee JH, Strakowski SM. Neurochemical effects of quetiapine in patients with bipolar mania: a proton magnetic resonance spectroscopy study. J Clin Psychopharmacology. 2013;33:528–32.CrossRefGoogle Scholar
  40. 40.
    Klasen M, Zvyagintsev M, Schwenzer M, Mathiak KA, Sarkheil P, Weber R, Mathiak K. Quetiapine modulates functional connectivity in brain aggression networks. Neuroimage. 2013;75:20–6.CrossRefPubMedGoogle Scholar
  41. 41.
    Masi G, Liboni F. Management of schizophrenia in children and adolescents: focus on pharmacotherapy. Drugs. 2011;71:179–208.CrossRefPubMedGoogle Scholar
  42. 42.
    Cohen D, Bonnot O, Bodeau N, Consoli A, Laurent C. Adverse effects of second-generation antipsychotics in children and adolescents: a Bayesian meta-analysis. J Clin Psychopharmacol. 2012;32:309–16.CrossRefPubMedGoogle Scholar
  43. 43.
    McConville B, Carrero L, Sweitzer D, Potter L, Chaney R, Foster K, Sorter M, Friedman L, Browne K. Long-term safety, tolerability, and clinical efficacy of quetiapine in adolescents: an open-label extension trial. J Child Adolesc Psychopharmacol. 2003;13:75–82.CrossRefPubMedGoogle Scholar
  44. 44.
    Findling RL, Pathak S, Earley WR, Liu S, DelBello MP. Safety, tolerability, and efficacy of quetiapine in youth with schizophrenia or bipolar I disorder: a 26-week, open-label, continuation study. J Child Adolesc Psychopharmacol. 2013;23:490–501.CrossRefPubMedCentralPubMedGoogle Scholar
  45. 45.
    Fraguas D, Merchán-Naranjo J, Laita P, Parellada M, Moreno D, Ruiz-Sancho A, Cifuentes A, Giráldez M, Arango C. Metabolic and hormonal side effects in children and adolescents treated with second-generation antipsychotics. J Clin Psychiatry. 2008;69:1166–75.CrossRefPubMedGoogle Scholar
  46. 46.
    Noguera A, Ballesta P, Baeza I, Arango C, de la Serna E, González-Pinto A, Parellada M, Graell M, Moreno C, Otero S, Castro-Fornieles J. Twenty-four months of antipsychotic treatment in children and adolescents with first psychotic episode: discontinuation and tolerability. J Clin Psychopharmacol. 2013;33:463–71.CrossRefPubMedGoogle Scholar
  47. 47.
    Patel NC, Kistler JS, James EB, Crismon ML. A retrospective analysis of the short-term effects of olanzapine and quetiapine on weight and body mass index in children and adolescents. Pharmacotherapy. 2004;24:824–30.CrossRefPubMedGoogle Scholar
  48. 48.
    Correll CU, Manu P, Olshanskiy V, Napolitano B, Kane JM, Malhotra AK. Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA. 2009;302:1765–73.CrossRefPubMedCentralPubMedGoogle Scholar
  49. 49.
    Arango C, Giráldez M, Merchán-Naranjo J, Baeza I, Castro-Fornieles J, Alda JA, Martínez-Cantarero C, Moreno C, de Andrés P, Cuerda C, de la Serna E, Correll CU, Fraguas D, Parellada M. Second-generation antipsychotic use in children and adolescents: a six-month prospective cohort study in drug-naïve patients. J Am Acad Child Adolesc Psychiatry. 2014;53:1179–90.CrossRefPubMedGoogle Scholar
  50. 50.
    Jensen KG, Juul K, Fink-Jensen A, Correll CU, Pagsberg AK. Corrected QT changes during antipsychotic treatment of children and adolescents: a systematic review and meta-analysis of clinical trials. J Am Acad Child Adolesc Psychiatry. 2015;54(1):25–36.CrossRefPubMedGoogle Scholar
  51. 51.
    Hasnain M, Vieweg WV, Howland RH, Kogut C, Breden Crouse EL, Koneru JN, Hancox JC, Digby GC, Baranchuk A, Deshmukh A, Pandurangi AK. Quetiapine, QTc interval prolongation, and torsade de pointes: a review of case reports. Ther Adv Psychopharmacol. 2014;4:130–8.CrossRefPubMedCentralPubMedGoogle Scholar
  52. 52.
    Pringsheim T, Panagiotopoulos C, Davidson J, Ho J, CAMESA guideline group. Evidence-based recommendations for monitoring safety of second generation antipsychotics in children and youth. J Can Acad Child Adolesc Psychiatry. 2011;20:218–33.PubMedCentralPubMedGoogle Scholar
  53. 53.
    Arango C, Parellada M, Moreno DM. Clinical effectiveness of new generation antipsychotics in adolescent patients. Eur Neuropsychopharmacol. 2004;14:S471–9.CrossRefPubMedGoogle Scholar
  54. 54.
    Pagsberg AK, Jeppesen P, Klauber DG, Jensen KG, Rudå D, Stentebjerg-Olesen M, Jantzen P, Rasmussen S, Saldeen EA, Lauritsen MB, Bilenberg N, Stenstrøm AD, Pedersen J, Nyvang L, Madsen S, Lauritsen MB, Vernal DL, Thomsen PH, Paludan J, Werge TM, Winge K, Juul K, Gluud C, Skoog M, Wetterslev J, Jepsen JR, Correll CU, Fink-Jensen A, Fagerlund B. Quetiapine versus aripiprazole in children and adolescents with psychosis—protocol for the randomised, blinded clinical tolerability and efficacy of antipsychotics (TEA) trial. BMC Psychiatry. 2014;14:199.CrossRefPubMedCentralPubMedGoogle Scholar
  55. 55.
    Arango C, Bobes J. Managing acute exacerbations of schizophrenia: focus on quetiapine. Curr Med Res Opin. 2004;20:619–26.CrossRefPubMedGoogle Scholar
  56. 56.
    Correll CU, Penzner JB, Parikh UH, et al. Recognizing and monitoring adverse events of second-generation antipsychotics in children and adolescents. Child Adolesc Psychiatr Clin N Am. 2006;15:177–206.CrossRefPubMedGoogle Scholar
  57. 57.
    Cosgrove VE, Roybal D, Chang KD. Bipolar depression in pediatric populations: epidemiology and management. Paediatr Drugs. 2013;15:83–91.CrossRefPubMedGoogle Scholar
  58. 58.
    Young AH, Calabrese JR, Gustafsson U, Berk M, McElroy SL, Thase ME, Suppes T, Earley W. Quetiapine monotherapy in bipolar II depression: combined data from four large, randomized studies. Int J Bipolar Disord. 2013;1:10–7.CrossRefPubMedCentralPubMedGoogle Scholar
  59. 59.
    Panagiotopoulos C, Ronsley R, Elbe D, et al. First do no harm: promoting an evidence-based approach to atypical antipsychotic use in children and adolescents. J Can Acad Child Adolesc Psychiatry. 2010;19:124–37.PubMedCentralPubMedGoogle Scholar
  60. 60.
    McKean A, Monasterio E. Off-label use of atypical antipsychotics: cause for concern? CNS Drugs. 2012;26:383–90.CrossRefPubMedGoogle Scholar
  61. 61.
    Sansone RA, Sansone LA. Is seroquel developing an illicit reputation for misuse/abuse? Psychiatry. 2010;7:13–6.Google Scholar
  62. 62.
    Cha HJ, Lee HA, Ahn JI, Jeon SH, Kim EJ, Jeong HS. Dependence potential of quetiapine: behavioral pharmacology in rodents. Biomol Ther. 2013;21:307–12.CrossRefGoogle Scholar
  63. 63.
    Seida JC, Schouten JR, Boylan K, Newton AS, Mousavi SS, Beaith A, Vandermeer B, Dryden DM, Carrey N. Antipsychotics for children and young adults: a comparative effectiveness review. Pediatrics. 2012;129:771–84.CrossRefGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2015

Authors and Affiliations

  • Gabriele Masi
    • 1
  • Annarita Milone
    • 1
  • Stefania Veltri
    • 2
  • Raffaella Iuliano
    • 3
  • Chiara Pfanner
    • 1
  • Simone Pisano
    • 4
  1. 1.IRCCS Stella Maris, Scientific Institute of Child Neurology and PsychiatryPisaItaly
  2. 2.Unit of Child NeuropsychiatryCatholic UniversityRomeItaly
  3. 3.Department of PediatricsHospital “F. Veneziale”IserniaItaly
  4. 4.Child and Adolescent Psychiatry Division, Department of Mental and Physical Health and Preventive MedicineSecond University of NaplesNaplesItaly

Personalised recommendations